Cargando…
Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
BACKGROUND: Spinal muscular atrophy (SMA) is the most common neurodegenerative disease in childhood. Since motor neuron injury is usually not reversible, early diagnosis and treatment are essential to prevent major disability. Our objective was to assess the impact of genetic newborn screening for S...
Autores principales: | Vill, Katharina, Schwartz, Oliver, Blaschek, Astrid, Gläser, Dieter, Nennstiel, Uta, Wirth, Brunhilde, Burggraf, Siegfried, Röschinger, Wulf, Becker, Marc, Czibere, Ludwig, Durner, Jürgen, Eggermann, Katja, Olgemöller, Bernhard, Harms, Erik, Schara, Ulrike, Kölbel, Heike, Müller-Felber, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011100/ https://www.ncbi.nlm.nih.gov/pubmed/33789695 http://dx.doi.org/10.1186/s13023-021-01783-8 |
Ejemplares similares
-
Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening – Opportunity or Burden?(1)
por: Müller-Felber, Wolfgang, et al.
Publicado: (2020) -
One Year of Newborn Screening for SMA – Results of a German Pilot Project
por: Vill, Katharina, et al.
Publicado: (2019) -
Molecular based newborn screening in Germany: Follow-up for cystinosis
por: Hohenfellner, Katharina, et al.
Publicado: (2019) -
Newbornscreening SMA – From Pilot Project to Nationwide Screening in Germany
por: Müller-Felber, Wolfgang, et al.
Publicado: (2023) -
Parental Burden and Quality of Life in 5q-SMA Diagnosed by Newborn Screening
por: Kölbel, Heike, et al.
Publicado: (2022)